Trilogy gets first stamp of approval from analysts
Craigs initiates first coverage of the stock, sets profit guidance for the year. With special feature audio.
Natural skincare and fragrance maker Trilogy International [NZX:TIL] has received a stamp of approval from Craigs Investment Partners, which initiated coverage of the stock this week.
Trilogy has been a strong performer on the NZX since listing in 2010 but has never been covered by analysts due
Want to read more? It's easy.
Choose your best value subscription option
Individual
Group membership
NBR Marketplace
Yearly Premium Online Subscription
NZ$499.00 / yearly
Monthly Premium Online Subscription
NZ$44.95 / monthly
Smartphone Only Subscription
NZ$24.95 / monthly
Premium Group Membership 10 Users
NZ$350+GST / monthly
$35 per user - Pay by monthly credit card debitPremium Group Membership 20 Users
NZ$600+GST / monthly
$30 per user - Pay by monthly credit card debitPremium Group Membership 50 Users
NZ$1250+GST / monthly
$25 per user - Pay by monthly credit card debitPremium Group Membership 100 Users
NZ$1875+GST / monthly
$18.75 per user - Pay by monthly credit card debitYearly Premium Online Subscription + NBR Marketplace
NZ$499.00 / yearly
Already have an account? Login
Calida Smylie
Wed, 07 Sep 2016
Wed, 07 Sep 2016
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Trilogy gets first stamp of approval from analysts
61425